NCT03618381: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 1 Year to 26 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Patient must have s solid tumor expressing EGFR
Exclusions: Patients over the age of 26

Comments are closed.

Up ↑